RE:RE:U of Alberta & Drs. Lilge & McFarland Paper Now Available My bet is that a bigger pharma than Astellas could suit us much better. Royalties would be much higher in terms of revenues with a pharma that has a larger urology network. My guts feeling is Roche, the top 3 largest big pharmas, as they are also present in our 3 fields of expertise; urology, neurology and pulmonary. This could prove to be attractive to them if they decide to make a move on PDT/PDC.
Nevertheless, Astellas also already have a foot in the uro field with 2 products.
https://www.astellasresources.com/urology-resources
They are present in Europe as per this urology Greece page:
https://www.astellas.com/gr/en/innovation/therapeutic-areas/urology
And in 2012, they came up with this first CUA grant:
https://www.astellas.com/ca/system/files/news/2018-09FINAL%20-%20CUA%20Astellas%20ResearchGrant%20winners_1.pdf
_____________
Camphikefish - (8/28/2023 2:01:58 PM)
RE:U of Alberta & Drs. Lilge & McFarland Paper Now Available
As of June 2023 Astellas Pharma has $4.16 Billion Cash on Hand. For what it's worth. 1433 looks like a very fitting dovetail into their product portfolio. Also seems some combo potential with their existing drug(s) are a very viable option. Who knows.